Fidelity Investments’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Fidelity Investments’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-43,178	Closed	-$1.57M	–	3896
2018 Q2	$1.57M	Hold	43,178	–	–	﹤0.01%	2379
2018 Q1	$1.35M	Sell	43,178 -10,673	-20%	-$339K	﹤0.01%	2412
2017 Q4	$2.08M	Sell	53,851 -17,280	-24%	-$453K	﹤0.01%	2351
2017 Q3	$1.51M	Sell	71,131 -2,767	-4%	-$51.4K	﹤0.01%	2368
2017 Q2	$1.49M	Sell	73,898 -2,300	-3%	-$47.6K	﹤0.01%	2389
2017 Q1	$1.7M	Sell	76,198 -4,340	-5%	-$68.2K	﹤0.01%	2379
2016 Q4	$633K	Hold	80,538	–	–	﹤0.01%	2531
2016 Q3	$1.69M	Hold	80,538	–	–	﹤0.01%	2394
2016 Q2	$2.09M	Sell	80,538 -3,994	-5%	-$110K	﹤0.01%	2376
2016 Q1	$3.12M	Sell	84,532 -2,273	-3%	-$84.3K	﹤0.01%	2274
2015 Q4	$3.85M	Hold	86,805	–	–	﹤0.01%	2272
2015 Q3	$6.76M	Hold	86,805	–	–	﹤0.01%	2088
2015 Q2	$10.3M	Hold	86,805	–	–	﹤0.01%	1998
2015 Q1	$12M	Buy	+86,805	New	+$13.5M	﹤0.01%	1932

Other funds holding BLPH

NMVA

New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Fidelity Investments's BLPH Position: Q3 2018 in Review

Fidelity Investments sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2018, closing a stake of 43,178 shares — an estimated $1.57M sold.

Fidelity Investments first reported a position in BLPH in Q1 2015 and held it in 14 quarters. The position peaked at $12M in Q1 2015. 30 funds tracked by Wall St. Rank hold BLPH as of Q3 2018.

Fidelity Investments reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Fidelity Investments sold 43,178 Bellerophon Therapeutics, Inc. shares in Q3 2018, an estimated $1.57M.
Fidelity Investments first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 14 quarters.
Fidelity Investments's Bellerophon Therapeutics, Inc. position peaked at $12M in Q1 2015.
30 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2018.

Based on Fidelity Investments's 13F filing for Q3 2018, filed 9 Nov 2018.